ProKidney develops rilparencel, a cell therapy aimed at preserving kidney function in people with chronic kidney disease and diabetes. PROK reports earnings on Mon, Nov 9, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 28 | Citigroup | Maintained | Buy | |
| May 18 | HC Wainwright & Co. | Reiterated | Buy |
Seasonality
How PROK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in PROK in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PROK is in one of them and how their past PROK trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PROK in an article yet. Here's the latest on the wider market.
About Prokidney
ProKidney is a biotechnology company developing rilparencel, a cell therapy meant to preserve kidney function in patients with chronic kidney disease and type 2 diabetes. The treatment is made from a patient's own kidney cells, which are collected from a small kidney biopsy, processed at the company's facility, and then injected back into the kidneys. The company is based in Winston-Salem, North Carolina, and its product is still in clinical development.
- Headquarters
- Winston-Salem, NC